Unique Wealth LLC Raises Stake in Johnson & Johnson (NYSE:JNJ)

Posted by Defense World Staff on Oct 10th, 2023

Unique Wealth LLC raised its stake in Johnson & Johnson (NYSE:JNJ – Free Report) by 2.3% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 5,956 shares of the company’s stock after purchasing an additional 132 shares during the quarter. Johnson & Johnson accounts for 0.4% of Unique Wealth LLC’s portfolio, making the stock its 24th biggest position. Unique Wealth LLC’s holdings in Johnson & Johnson were worth $986,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. DORCHESTER WEALTH MANAGEMENT Co raised its holdings in shares of Johnson & Johnson by 8.6% during the first quarter. DORCHESTER WEALTH MANAGEMENT Co now owns 67,618 shares of the company’s stock valued at $14,975,000 after acquiring an additional 5,327 shares in the last quarter. Cantor Fitzgerald Investment Advisor L.P raised its holdings in shares of Johnson & Johnson by 88.9% during the first quarter. Cantor Fitzgerald Investment Advisor L.P now owns 175,194 shares of the company’s stock valued at $31,049,000 after acquiring an additional 82,429 shares in the last quarter. AMI Investment Management Inc. raised its holdings in shares of Johnson & Johnson by 8.8% during the first quarter. AMI Investment Management Inc. now owns 18,305 shares of the company’s stock valued at $3,244,000 after acquiring an additional 1,475 shares in the last quarter. Equitable Holdings Inc. raised its holdings in shares of Johnson & Johnson by 4.9% during the first quarter. Equitable Holdings Inc. now owns 45,673 shares of the company’s stock valued at $8,095,000 after acquiring an additional 2,119 shares in the last quarter. Finally, USS Investment Management Ltd raised its holdings in shares of Johnson & Johnson by 2.4% during the first quarter. USS Investment Management Ltd now owns 860,371 shares of the company’s stock valued at $152,488,000 after acquiring an additional 20,528 shares in the last quarter. Institutional investors own 68.40% of the company’s stock.

Johnson & Johnson Trading Up 0.6 %

Johnson & Johnson stock opened at $158.53 on Tuesday. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.12 and a quick ratio of 0.88. Johnson & Johnson has a one year low of $150.11 and a one year high of $181.04. The stock has a market capitalization of $412.01 billion, a PE ratio of 32.09, a price-to-earnings-growth ratio of 3.19 and a beta of 0.55. The business’s fifty day moving average is $164.12 and its 200 day moving average is $162.46.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last released its quarterly earnings data on Thursday, July 20th. The company reported $2.80 EPS for the quarter, beating the consensus estimate of $2.62 by $0.18. Johnson & Johnson had a return on equity of 36.72% and a net margin of 13.35%. The company had revenue of $25.53 billion for the quarter, compared to analysts’ expectations of $24.63 billion. During the same period last year, the firm posted $2.59 earnings per share. Johnson & Johnson’s revenue was up 6.3% compared to the same quarter last year. On average, sell-side analysts predict that Johnson & Johnson will post 10.02 EPS for the current year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Thursday, September 7th. Shareholders of record on Monday, August 28th were issued a $1.19 dividend. This represents a $4.76 dividend on an annualized basis and a yield of 3.00%. The ex-dividend date was Friday, August 25th. Johnson & Johnson’s dividend payout ratio is 96.36%.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, insider William Hait sold 14,698 shares of the stock in a transaction dated Wednesday, July 26th. The stock was sold at an average price of $172.00, for a total value of $2,528,056.00. Following the transaction, the insider now owns 87,747 shares of the company’s stock, valued at $15,092,484. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other Johnson & Johnson news, insider William Hait sold 14,698 shares of the stock in a transaction dated Wednesday, July 26th. The stock was sold at an average price of $172.00, for a total value of $2,528,056.00. Following the transaction, the insider now owns 87,747 shares of the company’s stock, valued at $15,092,484. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, VP Peter Fasolo sold 20,000 shares of the stock in a transaction dated Tuesday, July 25th. The shares were sold at an average price of $170.32, for a total value of $3,406,400.00. Following the completion of the transaction, the vice president now directly owns 102,696 shares in the company, valued at approximately $17,491,182.72. The disclosure for this sale can be found here. 0.20% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on JNJ. Raymond James decreased their target price on Johnson & Johnson from $184.00 to $179.00 and set an “outperform” rating for the company in a report on Tuesday, September 5th. Atlantic Securities upped their price target on Johnson & Johnson from $167.00 to $170.00 and gave the stock a “neutral” rating in a research note on Friday, August 4th. Stifel Nicolaus upped their price target on Johnson & Johnson from $165.00 to $175.00 in a research note on Friday, July 21st. TheStreet raised Johnson & Johnson from a “c+” rating to a “b+” rating in a research note on Monday, August 21st. Finally, StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Friday, September 29th. Nine research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Johnson & Johnson has a consensus rating of “Moderate Buy” and an average target price of $171.06.

View Our Latest Stock Report on JNJ

About Johnson & Johnson

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.